L L Johnson

Summary

Affiliation: Parke-Davis Pharmaceutical Research
Country: USA

Publications

  1. ncbi request reprint Matrix metalloproteinases
    L L Johnson
    Department of Biochemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Curr Opin Chem Biol 2:466-71. 1998
  2. ncbi request reprint Effect of species differences on stromelysin-1 (MMP-3) inhibitor potency. An explanation of inhibitor selectivity using homology modeling and chimeric proteins
    L L Johnson
    Department of Cancer Research, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    J Biol Chem 274:24881-7. 1999
  3. ncbi request reprint A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition
    L L Johnson
    Department of Cancer Research, Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, Michigan 48105, USA
    J Biol Chem 275:11026-33. 2000
  4. pmc X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity
    A G Pavlovsky
    Department of Chemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Protein Sci 8:1455-62. 1999
  5. ncbi request reprint Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors
    P M O'Brien
    Department of Chemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 43:156-66. 2000
  6. ncbi request reprint X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily
    V Dhanaraj
    Department of Crystallography, Birkbeck College, London, UK
    Structure 4:375-86. 1996
  7. ncbi request reprint Complete amino acid sequence of human serum cholinesterase
    O Lockridge
    J Biol Chem 262:549-57. 1987

Collaborators

  • J Chen
  • A G Pavlovsky
  • Adam R Johnson
  • P M O'Brien
  • D F Ortwine
  • V Dhanaraj
  • J A Picard
  • R D Dyer
  • D R Sliskovic
  • C F Man
  • B D Roth
  • H Hallak
  • J R Rubin
  • D J Hupe
  • J B Dunbar
  • C Humblet
  • T L Blundell
  • Q Z Ye
  • O Lockridge
  • C F Bartels
  • C K Wong
  • T A Vaughan
  • S E Norton

Detail Information

Publications7

  1. ncbi request reprint Matrix metalloproteinases
    L L Johnson
    Department of Biochemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Curr Opin Chem Biol 2:466-71. 1998
    ..In addition, more selective inhibitors with improved pharmacokinetic profiles have entered clinical trials, allowing the assessment of the safety and efficacy of this strategy...
  2. ncbi request reprint Effect of species differences on stromelysin-1 (MMP-3) inhibitor potency. An explanation of inhibitor selectivity using homology modeling and chimeric proteins
    L L Johnson
    Department of Cancer Research, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    J Biol Chem 274:24881-7. 1999
    ..Homology modeling provides a tool to identify key differences in isoforms that can significantly affect native enzyme activity...
  3. ncbi request reprint A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition
    L L Johnson
    Department of Cancer Research, Parke Davis Pharmaceutical Research, Division of Warner Lambert Co, Ann Arbor, Michigan 48105, USA
    J Biol Chem 275:11026-33. 2000
    ..The striking acidic profile of stromelysin-1 defined by the combined ionization of Glu(202) and His(224) allows the design of highly selective inhibitors...
  4. pmc X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity
    A G Pavlovsky
    Department of Chemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Protein Sci 8:1455-62. 1999
    ..An analysis of the unique binding mode predicts structural modifications to design improved MMP inhibitors...
  5. ncbi request reprint Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors
    P M O'Brien
    Department of Chemistry, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 43:156-66. 2000
    ....
  6. ncbi request reprint X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily
    V Dhanaraj
    Department of Crystallography, Birkbeck College, London, UK
    Structure 4:375-86. 1996
    ..Matrixins play key roles in diseases as diverse as arthritis and cancer and hence are important targets for therapeutic intervention...
  7. ncbi request reprint Complete amino acid sequence of human serum cholinesterase
    O Lockridge
    J Biol Chem 262:549-57. 1987
    ..The sequence of human serum cholinesterase is 53.8% identical with the sequence of acetylcholinesterase from Torpedo californica and 28% identical with the carboxyl-terminal portion of bovine thyroglobulin...